Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Quantitative Estimation of Thrombus Burden in Patients With STEMI Using Micro-Computed Tomography (QUEST-STEMI) (QUEST-STEMI)

7 de julho de 2020 atualizado por: Karagiannidis Efstratios, Aristotle University Of Thessaloniki

Quantitative Estimation of Thrombus Burden in Patients With ST Elevation Acute Myocardial Infarction (STEMI) With the Use of Micro-computed Tomography-A Methodological Approach (QUEST-STEMI)

The study aims to assess for the first time, through the application of innovative technologies (micro-CT), important characteristics of aspirated thrombi (such as their volume and their density), which might be linked to certain clinical outcomes, in patients presenting with STEMI and referred for primary Percutaneous Coronary Intervention (PCI). To this end, a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi will be developed. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume and their density will be calculated with the use of micro-CT. Having a better resolution than conventional computed tomography, micro-CT will allow us to create 3D models of aspirated thrombi from a series of x-ray projection images. These 3D models will be further analyzed in order to find the volume and the density of aspirated thrombi. Shape analysis of the surface of aspirated thrombi and potential differences in their structure will also be assessed. Correlation of these variables with clinical parameters and angiographic outcomes will be attempted.

Thus, a risk-stratification model will be developed combining:

  • Clinical and laboratory data,
  • Angiographic parameters,
  • Data regarding the volume, the density and the composition of aspirated thrombi.

This model will enable the stratification of the cardiovascular and cerebrovascular risk of patients and the identification of who will benefit from thrombus aspiration, providing a personalized approach in treating patients with STEMI.

Visão geral do estudo

Status

Concluído

Descrição detalhada

Acute myocardial infarction with ST elevation (STEMI) remains one of the leading causes of mortality in developed countries, in spite of the important advances in pharmacological therapy and in mechanical reperfusion therapy. Having an important role in provoking ischemia, thrombus has been studied in many clinical trials and high thrombus burden has been proven to be an independent risk factor for stent thrombosis and for Major Adverse Clinical outcomes. However large randomized controlled trials concerning thrombus aspiration showed controversial results, providing as a whole no evidence of distinct benefits for thrombus aspiration. A possible explanation could be that aspiration was performed as a routine strategy in all of these trials, whereas these patients should be considered as a heterogeneous group and thus they should be risk-stratified. For this reason, it is of paramount importance to classify patients according to the volume of thrombus burden. The currently existing classifications of thrombus burden (the most important being those of Gibson and of Sianos) are based on visual assessment of angiographic characteristics and thus they are not reflecting the volume of the thrombi in actual, absolute numbers.

The main purpose of the study is to develop a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi in patients presenting with STEMI and referred for primary PCI. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume will be calculated with the use of micro-CT. The scanning procedure results into a series of projection images arranged in the form of image stacks which, in turn, are reformed in sections (cross section images) with the use of the NRecon (Bruker, Kontich, Belgium) software, which applies a modified algorithm of backward projection Feldkamp. The resulting sections will be combined to create the 3D models which will be further analyzed to extract useful measurements for the characteristics of the thrombi, such as for the volume and the elative density. Shape analysis on the surface and internal structure of the three-dimensional representations of the specimens will lead to the identification of the important features that can be used to estimate variability within samples and perform clustering for the significant differences between clots. In addition, possible differences in clot internal and external structure (e.g. architecture of the various cell types) will be assessed through the 3D models rendered from the stacks of images The Secondary end points of the study include the examination of the association of the aforementioned variables with the angiographic classification of thrombus burden (according to Sianos), with electrocardiographic and angiographic characteristics suggestive of poor patient prognosis and with major adverse cardiac events during the follow-up period of one year.

This method could become the gold standard for the exact measurement of thrombus burden and could be used in larger, clinically-oriented trials to help stratify patients with thrombus burden according to their risk for adverse outcomes.

Tipo de estudo

Observacional

Inscrição (Real)

115

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Thessaloníki, Grécia, 54636
        • University General Hospital of Thessaloniki AHEPA

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra de Probabilidade

População do estudo

consecutive patients presenting with ST elevation myocardial infarction, who undergo primary PCI and thrombus aspiration

Descrição

Inclusion Criteria:

  • Patients presenting with symptoms of myocardial ischemia lasting for more than 30 minutes
  • Definite ECG changes indicating STEMI
  • Patients undergoing primary PCI within 12 hours from symptom onset
  • Possibility to perform thrombus aspiration
  • Age>18 years
  • Written informed consent prior to enrolment in the clinical trial

Exclusion Criteria:

  • Treatment with fibrinolytic therapy for qualifying index STEMI event
  • Patients with known intolerance to aspirin, ticagrelor or heparin
  • Patients with active internal bleeding
  • Patients with a recent history of intracranial hemorrhage

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: Caso-somente
  • Perspectivas de Tempo: Prospectivo

Coortes e Intervenções

Grupo / Coorte
pacientes com baixa carga de trombo
pacientes com o menor volume de trombos aspirados, conforme medido usando micro-CT
pacientes com alta carga de trombos
pacientes com maior volume de trombos aspirados, conforme medido usando micro-CT

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
volume of aspirated thrombus burden
Prazo: 12 months
The volume of aspirated thrombi will be quantified using micro-CT.
12 months
density of aspirated thrombus burden
Prazo: 12 months
The density of aspirated thrombi will be quantified using micro-CT.
12 months
MACCE-free survival
Prazo: 12 months
Time between the date of diagnosis and MACCE during the follow-up period of 12 months. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
association between thrombus volume with factors from patients medical history
Prazo: 12 months
Potential association of thrombus volume (as assessed using micro-ct) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
12 months
association between thrombus density with factors from patients medical history
Prazo: 12 months
Potential association of thrombus density ( as assessed using micro-CT) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
12 months
Correlation of the volume of aspirated thrombus burden with the Sianos' classification of thrombus burden
Prazo: 12 months
Potential correlation of the volume of aspirated thrombus burden, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored. According to Sianos' classification thrombi are classified in the following categories: G0,G1,G2,G3,G4.
12 months
Correlation of thrombus density with the Sianos' classification of thrombus burden
Prazo: 12 months
Potential correlation of thrombus density, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored.
12 months
association of thrombus volume with electrocardiographic outcomes suggestive of poor patient prognosis
Prazo: 12 months
Potential association of thrombus volume as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
12 months
association of thrombus density with electrocardiographic outcomes suggestive of poor patient prognosis
Prazo: 12 months
Potential association of thrombus density as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
12 months
association of thrombus volume with post-procedural Thrombolysis in Myocardial Infarction(TIMI) flow
Prazo: 12 months
Potential association of thrombus volume as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
12 months
association of thrombus density with post-procedural TIMI flow
Prazo: 12 months
Potential association of thrombus density as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
12 months
association of thrombus volume with myocardial blush grade
Prazo: 12 months
Potential association of thrombus volume as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
12 months
association of thrombus density with myocardial blush grade
Prazo: 12 months
Potential association of thrombus density as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
12 months
association of thrombus volume with distal embolization .
Prazo: 12 months
Potential association of thrombus volume as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
12 months
association of thrombus density with distal embolization .
Prazo: 12 months
Potential association of thrombus density as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
12 months
association of thrombus volume with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Prazo: 12 months
Potential association of thrombus volume, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months
association of thrombus density with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Prazo: 12 months
Potential association of thrombus density, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Cadeira de estudo: Georgios Sianos, MD,PhD, FESC, Associate Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Investigador principal: Efstratios Karagiannidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
  • Investigador principal: Charalambos Karvounis, MD,Phd, Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Investigador principal: George Giannakoulas, MD,Phd, Assistant Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Investigador principal: Christos Arvanitidis, Phd, Director of Research, Hellenic Center for Marine Research
  • Investigador principal: Ioannis Vizirianakis, PharmD, PhD, Associate Professor, School of Pharmacy, Aristotle University of Thessaloniki
  • Investigador principal: James S Michaelson, MD,Phd, Associate Professor, Department of Pathology, Harvard Medical School
  • Investigador principal: Kleoniki Keklikoglou, MSc, HELLENIC CENTER FOR MARINE RESEARCH
  • Investigador principal: Ivelin Samra, MD, Head of cardiology department at MHAT"Hadzy Dimityr" Sliven
  • Investigador principal: Nikolaos Konstantinidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
  • Investigador principal: Georgios Sofidis, MD,Phd, Aristotle University Of Thessaloniki

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

25 de janeiro de 2018

Conclusão Primária (Real)

7 de julho de 2020

Conclusão do estudo (Real)

7 de julho de 2020

Datas de inscrição no estudo

Enviado pela primeira vez

25 de janeiro de 2018

Enviado pela primeira vez que atendeu aos critérios de CQ

5 de fevereiro de 2018

Primeira postagem (Real)

12 de fevereiro de 2018

Atualizações de registro de estudo

Última Atualização Postada (Real)

8 de julho de 2020

Última atualização enviada que atendeu aos critérios de controle de qualidade

7 de julho de 2020

Última verificação

1 de julho de 2020

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

Indeciso

Descrição do plano IPD

The decision to share or not individual participant data with other researchers will depend on the purpose and the scope of the proposed research

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

3
Se inscrever